To understand why the finding matters, it helps to start with the chemistry. N6-methyladenosine, abbreviated m6A, is the most abundant internal modification found in eukaryotic messenger RNA. Rather than changing the genetic code itself, m6A acts like a sticky note attached to individual transcripts, influencing how long they survive, how efficiently they are translated into protein, and where they travel within the cell. The system relies on a cast of molecular actors: writers that deposit the methyl group, erasers that remove it, and readers such as YTHDF2 that interpret the mark and decide the fate of the tagged RNA. When YTHDF2 recognizes an m6A-modified transcript, it typically shepherds that mRNA toward degradation, effectively turning down the volume of the corresponding gene.

The research team, led by Da Gu, Huanmin Lou, Xiaojing Li, and colleagues at institutions including the First Affiliated Hospital of Anhui Medical University and Shandong First Medical University, began by mining public cancer databases. Their pan-cancer survey revealed that YTHDF2 is elevated across a range of tumor types, and in cutaneous melanoma specifically, its expression levels correlated positively with PD-L1, the molecular beacon that tumors use to suppress immune attack. Intriguingly, higher YTHDF2 also tracked with lower immune and stromal scores, suggesting that tumors rich in this RNA reader may build microenvironments that are less hospitable to infiltrating immune cells. That combination of immune evasion and aggressive growth made YTHDF2 a compelling suspect in the search for drivers of melanoma malignancy.

The next step was to ask what happens when YTHDF2 is removed. Using melanoma cell lines in the laboratory, the researchers knocked down the protein and observed a striking cascade of effects. Cell proliferation slowed markedly, and the population of Annexin V and propidium iodide positive cells, standard markers of dying cells, climbed. Crucially, when the team added a ferroptosis inhibitor to the cultures, the damage was largely rescued. That rescue experiment was the pivotal clue: it indicated that the cell death triggered by YTHDF2 loss was not ordinary apoptosis, but ferroptosis, an iron-dependent form of regulated cell death defined by the catastrophic oxidation of lipid membranes.

Ferroptosis has become one of the hottest topics in cancer biology precisely because tumor cells seem to fear it. The biochemical signature is unmistakable. In the YTHDF2-depleted melanoma cells, the researchers measured rising levels of intracellular ferrous iron, malondialdehyde, reactive oxygen species, and lipid peroxidation products, all hallmarks of membranes under oxidative assault. At the same time, glutathione, the cell’s principal antioxidant shield, dwindled. Every one of these changes was reversed when ferroptosis was pharmacologically blocked, confirming that the iron-fueled lipid destruction pathway was the mechanism at work. Experiments in animal models corroborated the same regulatory relationship in living tumors, lending physiological weight to the cell culture findings.

But how does an RNA-binding protein control a cell death pathway built from iron and lipids? The answer emerged from an integrated analysis combining RNA sequencing with RIP sequencing, a technique that maps which transcripts a protein physically binds. The data showed that YTHDF2 latches onto m6A marks on the messenger RNA of HMOX1, the gene encoding heme oxygenase 1, an enzyme with well-documented antioxidant and cytoprotective functions. By binding the methylated HMOX1 transcript, YTHDF2 destabilizes it, hastening its degradation and thereby suppressing the production of heme oxygenase 1. With less of this protective enzyme available, melanoma cells become more vulnerable to oxidative damage, yet the study’s overall picture shows that YTHDF2’s net effect in tumors is to promote malignant progression, positioning HMOX1 regulation as a key node in the network the protein controls.

The HMOX1 connection resonates with a growing body of literature. Heme oxygenase 1 has been implicated in ferroptosis regulation across diverse contexts, from liver cancer, where upregulating the enzyme synergizes with drug-induced ferroptotic stress, to retinal neovascularization and pulmonary hypertension, where YTHDF2 has separately been shown to suppress Hmox1-dependent antioxidant function in macrophages. The melanoma study now extends this theme into skin cancer, suggesting that the YTHDF2–HMOX1 axis is a recurring module that cells, whether diseased or malignant, use to tune their antioxidant capacity. In melanoma, the balance appears to tip in favor of tumor survival, consistent with YTHDF2’s established reputation as an oncogenic reader in cancers ranging from bladder carcinoma to diffuse large B-cell lymphoma.

Perhaps the most headline-grabbing element of the study is the repurposing angle. Metformin, a cheap, decades-old biguanide taken by millions of people with type 2 diabetes, has accumulated a long list of putative anticancer properties in the scientific literature. The researchers demonstrated that metformin inhibits YTHDF2 expression in melanoma cells, and in doing so promotes ferroptosis. The finding builds on the group’s earlier work, published in Cancer Genet, showing that metformin regulates ferroptosis in skin cutaneous melanoma through the ATF3/NRF2 axis. Together, the two studies sketch a coherent model in which the widely used drug pushes melanoma cells toward iron-mediated self-destruction by converging on the epitranscriptomic machinery that guards their antioxidant defenses. It also aligns with reports in breast cancer, where metformin induces ferroptosis by inhibiting the UFMylation of the cystine transporter SLC7A11, hinting that ferroptosis induction may be a unifying theme in the drug’s anticancer profile.

The therapeutic implications are tantalizing but must be tempered with appropriate caution. YTHDF2 has emerged as a target of growing interest in the field, with recent commentary in Trends in Cell Biology arguing that attacking the protein can reshape the epitranscriptome and overcome therapy resistance in tumors. A study in Science Immunology in 2024 detailed YTHDF2’s role in regulating immune evasion from within tumor cells, and the new melanoma data add a ferroptosis dimension to that immune story, given the observed correlation between YTHDF2 and PD-L1 expression. If blocking YTHDF2 simultaneously sensitizes tumor cells to ferroptosis and strips away immune camouflage, combination strategies that pair YTHDF2-directed approaches with checkpoint inhibitors become an obvious line of future investigation. Metformin, already proven safe in humans, could in principle be folded into such regimens more rapidly than a purpose-built YTHDF2 inhibitor, though clinical trials would be needed to establish any benefit in melanoma patients.

There are also broader lessons here about the m6A–ferroptosis interface, a frontier that a 2024 review in Molecular Cancer flagged as a promising avenue for advancing tumor immunotherapy. Other readers have been caught manipulating the same cell death pathway: in hepatocellular carcinoma, hypoxia was shown to block ferroptosis by suppressing the writer METTL14, which in turn unleashed YTHDF2-dependent silencing of SLC7A11. The melanoma study inverts the logic, with YTHDF2 acting on HMOX1 rather than SLC7A11, but the underlying principle is the same. Cancer cells exploit RNA modifications to fine-tune the expression of antioxidant genes, and each new target identified, whether a transporter, an enzyme like heme oxygenase 1, or a stress-response factor, adds a potential pressure point at which therapy could tip the balance toward tumor destruction. For a disease as stubborn as melanoma, that growing map of vulnerabilities is welcome news, and the humble RNA tag at the center of it may prove to be one of the most consequential sticky notes in modern cancer research.

Subject of Research: The role of the m6A reader YTHDF2 in regulating HMOX1-mediated ferroptosis and malignant progression in cutaneous melanoma

Article Title: YTHDF2 drives malignant progression in cutaneous melanoma through m⁶A-dependent HMOX1-mediated ferroptosis

Article References: Gu, D., Sun, Y., Sun, J., Kang, W., Lou, H., & Li, X. (2026). YTHDF2 drives malignant progression in cutaneous melanoma through m⁶A-dependent HMOX1-mediated ferroptosis. Medical Oncology, 43(11), Article 316. https://doi.org/10.1007/s12032-026-03427-y

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03427-y

Keywords: melanoma, YTHDF2, m6A modification, ferroptosis, HMOX1, metformin, RNA methylation, PD-L1, lipid peroxidation, epitranscriptomics, skin cancer, cell death

The cells at the center of the story are podocytes, highly specialized epithelial cells that wrap around the tiny capillary loops of the glomerulus, the kidney’s filtration unit. Podocytes extend intricate foot processes that interlock to form slits through which blood is filtered, and their integrity is essential for keeping protein from leaking into the urine. When podocytes are injured or lost, the filtration barrier breaks down, proteinuria develops, and progressive scarring follows. Podocyte injury is widely regarded as a decisive event in diabetic kidney disease, which is why understanding exactly how high blood sugar damages these cells has become one of the most pressing questions in nephrology.

The new research focuses on an unexpected player: FTO, the fat-mass and obesity-associated protein. FTO first rose to fame through genome-wide association studies linking variants in its gene to human obesity, but it was later shown to be an enzyme that removes a specific chemical modification from RNA molecules. That modification, N6-methyladenosine, or m6A, is the most abundant internal mark on messenger RNA in higher organisms. By adding or erasing m6A, cells can fine-tune how long a given mRNA survives, how efficiently it is translated into protein, and how it is processed. In earlier work, the team had manipulated FTO in podocytes and performed parallel methylated RNA immunoprecipitation sequencing and RNA sequencing, a combination that reveals both which transcripts carry m6A marks and how overall gene expression changes. That screen pointed them toward early growth response 1, or EGR1, a transcription factor whose precise role in diabetic kidney disease had remained unclear.

The findings that followed connect the dots in a strikingly mechanistic way. The researchers demonstrated that FTO is critical to podocyte injury because it enhances the stability of EGR1 mRNA in a manner dependent on m6A and on YTHDF2, a reader protein that binds methylated RNA and directs its fate. In other words, by removing methyl marks from the EGR1 transcript, FTO protects that message from YTHDF2-mediated degradation, allowing more EGR1 protein to be produced. The team also found that EGR1 is elevated in podocytes taken from people with diabetic kidney disease, and that its levels correlate with estimated glomerular filtration rate and with 24-hour urinary protein, two clinical measures of how well the kidney is functioning and how badly the filter is leaking.

Experiments in cultured human podocytes reinforced the picture. When the cells were exposed to high glucose, mimicking the diabetic environment, EGR1 expression climbed. Silencing EGR1 eased both the injury and the inflammation that high glucose provokes in podocytes, while forcing the cells to overproduce EGR1 made the damage worse. This dose-and-direction relationship, in which turning the gene down protects and turning it up harms, is exactly what one would expect from a genuine driver of the disease process rather than a passive bystander.

The mechanistic core of the study lies in what EGR1 does once it is produced. Using chromatin immunoprecipitation, the researchers showed that EGR1 binds directly to the promoter of STING1, the gene encoding stimulator of interferon genes 1, a protein better known as a central hub of innate immune signaling. By occupying its promoter, EGR1 boosts STING1 transcription, which in turn activates the STING1/TBK1/NF-κB signaling cascade. This cascade is a classic inflammatory pathway: STING1 activates TBK1, a kinase that then activates NF-κB, a transcription factor that switches on a battery of inflammatory genes. The result is a self-reinforcing inflammatory attack on the podocyte from within, driven ultimately by an RNA modification laid down by FTO.

To test whether the pathway matters in a living organism, the team turned to mouse models of diabetes induced by streptozotocin and a high-fat diet, which together reproduce key features of the human disease. Using adeno-associated virus vectors to deliver genetic constructs specifically to podocytes, they deleted or upregulated EGR1 in these cells. The outcome was unambiguous. Podocyte-specific deletion of EGR1 significantly reduced podocyte and glomerular damage in the diabetic mice, preserving the structure of the filtration barrier. Conversely, when EGR1 was deliberately elevated in podocytes, the mice suffered worse podocyte injury and heavier proteinuria. The same gene that protected cells when removed caused harm when amplified, confirming EGR1 as a pivotal node in the disease cascade in vivo.

The study is notable for the way it stitches together three layers of biology that are usually studied separately: epitranscriptomics, the chemistry of RNA modifications; transcriptional regulation, the control of gene expression by DNA-binding factors; and innate immunity, the inflammatory machinery that cells deploy against perceived threats. In the podocytes of a diabetic kidney, these layers converge into a single pathway. High glucose and FTO activity conspire to stabilize EGR1 mRNA, EGR1 protein then switches on STING1, and the STING1/TBK1/NF-κB axis ignites inflammation that erodes the kidney’s filter. Each link in that chain is a potential point of intervention, and the authors suggest that EGR1 itself could be a prospective new treatment strategy for diabetic kidney disease.

The clinical stakes are considerable. Current therapy for diabetic kidney disease rests on controlling blood glucose and blood pressure and on blocking the renin-angiotensin system with drugs such as angiotensin-converting enzyme inhibitors, alongside newer agents including SGLT2 inhibitors. Yet a large fraction of patients still progress toward dialysis or transplant, so molecular targets that address the injury process itself, rather than its systemic drivers, are eagerly sought. Because EGR1 sits downstream of FTO and upstream of the inflammatory cascade, drugging it or its partners might blunt podocyte inflammation even when metabolic control is imperfect. Any such approach would need to reckon with the fact that EGR1 is an immediate-early transcription factor with many roles in other tissues, so specificity will be a central challenge for future drug development.

There are also caveats that temper the excitement. The human evidence consists of correlations between EGR1 levels in podocytes and clinical markers, which, while consistent with the mechanistic data, cannot by themselves prove causation in patients. The mouse model, though well established, does not capture every feature of human diabetic nephropathy, and the viral vectors used to manipulate EGR1 in podocytes are research tools rather than therapeutic vehicles. The published version of the study is open access, allowing clinicians and researchers worldwide to scrutinize the data, and the work was approved by the relevant ethics committees at Shandong Provincial Hospital with informed consent from all participants. Even so, the study offers something the field has lacked: a complete, testable narrative linking an RNA demethylase, a methylated mRNA, an immune signaling hub, and the slow-motion catastrophe of the diabetic glomerulus. If that narrative holds up in further studies, the humble chemical tag on a strand of RNA may turn out to be one of diabetes’ most consequential accomplices, and shutting down its effects could help millions of people keep their kidneys working longer.

Subject of Research: FTO-mediated m6A modification of EGR1 mRNA and its role in podocyte injury and inflammation in diabetic kidney disease

Article Title: FTO-mediated m6A modification of EGR1 mRNA promotes podocyte injury and inflammation via STING1 in diabetic kidney disease

Article References: Hu, J., Liu, Y., Lang, Y., Liu, B., Fan, X., Yang, M., Shen, N., Zhang, D., Zhang, X., Chai, S., Zeng, Z., Shang, J., Wang, R., & Lv, Z. (2026). FTO-mediated m6A modification of EGR1 mRNA promotes podocyte injury and inflammation via STING1 in diabetic kidney disease. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06474-w

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06474-w

Keywords: diabetic kidney disease, podocytes, FTO, EGR1, STING1, m6A modification, RNA demethylase, YTHDF2, NF-kappaB, inflammation, proteinuria, nephrology

The research team, led by scientists at the Reproductive Medical Center of the First Affiliated Hospital of Sun Yat-Sen University in Guangzhou, set out to determine what happens to early neural differentiation when BMAL1 is removed from the picture. Using CRISPR-Cas9 genome editing, they generated human embryonic stem cell lines lacking functional BMAL1 and then pushed those cells, alongside unedited controls, to differentiate into neural stem cells. The results were striking. Loss of BMAL1 did not compromise the cells’ pluripotency; the edited stem cells retained their characteristic ability to self-renew and to express the canonical markers of an undifferentiated state. What failed instead was the transition itself.

When the BMAL1-deficient cells were directed toward a neural fate, the process faltered at multiple levels. The cells formed defective neural rosettes, the distinctive rosette-shaped structures that emerging neural epithelial tissue normally organizes into during in vitro differentiation and that serve as a hallmark of successful neural induction. Gene expression analysis confirmed the visual impression: programs of neural lineage genes were broadly suppressed in the absence of BMAL1, while the pluripotency network remained stubbornly intact. In effect, the cells stayed parked in their stem cell identity, unable to execute the developmental script that would normally transform them into progenitors of the nervous system.

To understand how a circadian factor could exert such authority over this developmental decision, the researchers combined transcriptomic profiling with CUT&Tag, a technique that maps where a protein binds across the genome and which chemical marks accompany it. These experiments revealed that BMAL1 directly occupies and regulates genes involved in embryonic development and neurogenesis, placing it squarely upstream of the transcriptional events required for neural commitment. But transcriptional control alone could not account for everything the team observed, so they widened the lens to include a layer of regulation that operates after genes are transcribed: N6-methyladenosine, or m6A, the most abundant internal chemical modification found in eukaryotic messenger RNA.

m6A modification has emerged over the past decade as a master regulator of RNA fate. By methylating specific adenosine bases within transcripts, cells can influence how long a given RNA survives, how efficiently it is translated into protein, and how it is processed. The modification is installed by writer enzymes, removed by erasers, and interpreted by reader proteins, of which YTHDF2 is one of the best characterized, typically directing methylated transcripts toward degradation or altered translation. m6A is known to be a key regulator of early development, and the new study shows that its landscape is dramatically reshaped when BMAL1 is lost.

Integrated m6A profiling across the transcriptome demonstrated that the distribution of the modification was altered in BMAL1-deficient cells, with a particularly notable reduction in m6A enrichment near the transcription end sites of genes whose expression had declined. In other words, the downregulation of neural genes in these cells was accompanied by a specific erosion of m6A marks at the tail ends of their transcripts, hinting that BMAL1’s influence extends beyond simply switching genes on and off at the DNA level. The team then asked what might be responsible for this altered modification pattern and made a pivotal observation: although YTHDF2 RNA levels were not proportionally affected, the amount of YTHDF2 protein plummeted in cells lacking BMAL1.

The mechanism behind this protein loss turned out to be elegantly convoluted. Through a combination of binding assays and transcript analysis, the researchers showed that BMAL1 binds to an E-box motif, the classic DNA sequence recognized by circadian transcription factors, within the promoter of the YTHDF2 gene. Intriguingly, BMAL1 also regulates alternative splicing of YTHDF2 transcripts, biasing production toward a splice variant that carries a highly structured five-prime untranslated region, the segment of the RNA that precedes the protein-coding sequence. Highly structured untranslated regions impede the ribosome’s progress, and the team confirmed that this variant is translated with markedly reduced efficiency. The net consequence is that loss of BMAL1 drains the cellular pool of YTHDF2 protein through a combination of transcriptional and post-transcriptional effects on the same gene.

To establish that this mechanism is genuinely causal rather than merely correlative, the researchers performed two decisive experiments. First, they used genome editing to disrupt the E-box motif in the YTHDF2 promoter, severing BMAL1’s direct grip on the gene. These edited cells phenocopied BMAL1 deficiency, displaying impaired neural differentiation despite the presence of a normal BMAL1 gene, which confirmed that the promoter interaction is a required element of the pathway. Second, they carried out functional rescue experiments, forcing YTHDF2 overexpression in BMAL1-deficient cells. This intervention partially restored the neural differentiation defects, demonstrating that YTHDF2 sits downstream of BMAL1 in the causal chain and that replenishing it can compensate for a substantial share of the damage caused by losing the clock factor.

Taken together, the study delineates what the authors describe as a BMAL1-m6A-YTHDF2 regulatory axis, a pathway that integrates transcriptional control, RNA modification and translational regulation into a single governing circuit for early human neural differentiation. The conceptual significance of this integration is considerable. Circadian biology and epitranscriptomics, the study of RNA chemical modifications, have largely progressed as parallel fields, and this work provides one of the clearest demonstrations that a circadian factor can act as a command node connecting the two. It also reframes BMAL1 itself: a protein best known for driving rhythmic gene expression in mature tissues is revealed to be a developmental gatekeeper whose removal leaves stem cells developmentally stalled.

The findings also carry implications that extend well beyond the culture dish. Circadian disruption, whether from shift work, sleep irregularity or other modern lifestyle pressures, is increasingly associated with adverse pregnancy and neurodevelopmental outcomes, but the molecular routes linking clock perturbation to developmental failure have remained speculative. By identifying a concrete mechanism through which BMAL1 loss derails human neural specification, the study provides a testable framework for how circadian disturbance could contribute to neurodevelopmental disorders. For regenerative medicine, the work suggests that protocols for deriving neural cells from human pluripotent stem cells, which are foundational to disease modeling and future cell therapies, may need to account for circadian factor status and m6A reader levels as quality-control variables. And for basic biology, it raises the possibility that the circadian system’s influence on development is broader and deeper than the daily rhythms it is famous for, operating at the level of RNA chemistry to shape which cells become neurons in the first place.

Subject of Research: BMAL1 regulation of human embryonic stem cell neural differentiation via YTHDF2-dependent m6A modification

Article Title: BMAL1 regulates human embryonic stem cell neurodifferentiation through YTHDF2-dependent m6A modification

Article References: Cai, B., Wen, T., Wang, B., Zeng, Y., Hou, W., Liu, X., Jin, Z., Ge, X., Cun, Y., Zhou, C., & Xu, Y. (2026). BMAL1 regulates human embryonic stem cell neurodifferentiation through YTHDF2-dependent m6A modification. Genome Biology. https://doi.org/10.1186/s13059-026-04276-8

Image Credits: AI Generated

DOI: 10.1186/s13059-026-04276-8

Keywords: BMAL1, circadian rhythm, human embryonic stem cells, neural differentiation, m6A modification, YTHDF2, CRISPR-Cas9, neurodevelopment, RNA modification, neural stem cells, alternative splicing, Genome Biology

The study, led by Yinliang Zhang, Xiaochen Gai, Dong Zhao and Yongsheng Chang, with contributions from a team at Tianjin Medical University, Capital Medical University and Westlake University, began with a deceptively simple observation. When mice were exposed to cold, or when their fat cells were bathed in norepinephrine, the sympathetic neurotransmitter that surges during cold exposure, levels of ALKBH5 rose sharply in brown and subcutaneous fat. ALKBH5 belongs to a small family of enzymes that remove N6-methyladenosine, or m6A, the most abundant internal chemical modification on messenger RNA. By stripping these methyl marks, ALKBH5 can alter how long particular mRNA molecules survive before being degraded, and therefore how much protein the cell can manufacture from them.

Tracing the signal upstream, the investigators found that ALKBH5 expression is not a passive side effect of cold. Instead, norepinephrine binding to adrenergic receptors triggers the classic thermogenic signaling cascade: cyclic AMP accumulates, protein kinase A is activated, and the transcription factor CREB is phosphorylated and dispatched to the ALKBH5 gene, switching it on. Pharmacological tools confirmed the pathway’s logic. Forskolin and CW 008, which elevate cAMP signaling, boosted ALKBH5 expression in both mouse and human adipocytes, while the CREB inhibitor 666-15 and the PKA inhibitor H89 blunted that induction. In other words, the same sympathetic signal that commands fat cells to burn also instructs them to reprogram their RNA landscape.

The consequences of losing that reprogramming became clear when the team generated mice lacking ALKBH5 specifically in adipose tissue. Both male and female animals showed reduced thermogenic capacity, dropping their body temperature faster during acute cold exposure and dissipating less energy overall. When fed a high-fat diet, the knockout mice gained more weight, accumulated more fat mass and developed impaired glucose homeostasis compared with controls. Crucially, the metabolic defect appeared without changes in food intake or locomotor activity, pointing squarely at energy expenditure rather than appetite as the underlying problem. The findings applied across sexes, strengthening the physiological relevance of the pathway.

The mirror-image experiment proved equally striking. When the researchers delivered an ALKBH5 gene into brown and subcutaneous fat using adeno-associated virus, the treated animals became metabolic overachievers. They maintained higher core body temperatures in the cold, generated greater total energy expenditure, and resisted the weight gain and glucose intolerance induced by a high-fat diet. Human data added a correlative dimension: analysis of gene expression from public cohorts, including the Genotype-Tissue Expression project, showed that ALKBH5 levels in human subcutaneous fat inversely correlate with obesity, suggesting that the mouse findings may translate to human biology.

The deepest insight, however, came from the mechanistic work. Searching for the thermogenic machinery that ALKBH5 controls, the team landed on CKB, creatine kinase B, an enzyme central to the so-called futile creatine cycle. In this circuit, creatine kinase pumps phosphate onto creatine to build phosphocreatine, and a mitochondrial enzyme hydrolyzes it back again, forcing the cell to burn ATP in a loop that generates heat rather than useful work. Deleting ALKBH5 from fat lowered CKB expression and creatine kinase activity, while boosting ALKBH5 raised them. When the researchers depleted creatine with beta-guanidinopropionic acid, the thermogenic benefits of ALKBH5 overexpression largely evaporated, confirming that creatine metabolism is the load-bearing element of the pathway.

Molecularly, the connection between the demethylase and the creatine kinase is an elegant piece of RNA biology. ALKBH5 removes m6A marks from the CKB transcript itself. Those methyl tags, when present, are recognized by YTHDF2, a reader protein that escorts methylated mRNAs to degradation machinery. By demethylating CKB mRNA, ALKBH5 shields it from YTHDF2-mediated destruction, lengthening the transcript’s half-life and allowing more creatine kinase B protein to be produced. Experiments with mutated CKB constructs, methylated RNA immunoprecipitation, and YTHDF2 knockdown in both mouse brown and human beige adipocytes pieced this mechanism together site by site, and the m6A peaks identified on CKB mRNA matched the canonical DRACH sequence motifs predicted from genomic analysis.

Perhaps the most provocative result concerns UCP1, the long-reigning icon of thermogenesis. In mice genetically engineered to lack UCP1 entirely, ALKBH5 overexpression still raised energy expenditure and protected against cold exposure, demonstrating that the creatine-driven pathway operates in parallel with, and independently of, the classical uncoupling mechanism. This echoes recent single-cell studies suggesting that thermogenic fat contains distinct subpopulations of cells, some defined by UCP1 and others by futile cycling enzymes. The new work provides the first known regulatory link between an adrenergic signal and the creatine branch, effectively giving that parallel pathway its own commander.

The therapeutic implications are considerable. Obesity treatments based on increasing energy expenditure have long sought safe ways to activate thermogenic fat, but UCP1-centric strategies face hurdles, including uncertainty about how much functional brown fat adult humans carry and concerns about off-target adrenergic stimulation. A target that works through mRNA stabilization rather than receptor agonism, and that functions even without UCP1, opens a genuinely different door. The authors caution that ALKBH5 is a broad-acting demethylase implicated in diverse processes, from fertility to cancer metabolism to cardiac fibrosis, so any obesity therapy built on it would need careful tissue specificity. Still, the demonstration that a single RNA modification enzyme can rewire cellular fuel chemistry in response to cold reframes thermogenesis as an epitranscriptomic phenomenon, and it hands obesity researchers a new molecular lever precisely where they need it most: the fat that burns.

Subject of Research: The role of the m6A demethylase ALKBH5 in regulating creatine-driven non-shivering thermogenesis in adipose tissue

Article Title: ALKBH5 activates creatine-driven thermogenesis by stabilizing CKB mRNA in response to cold

Article References: Zhang, Y., Du, C., Qiao, W., Qiu, P., Xu, C., Yang, X., Hao, J., Zhao, D., Gai, X., & Chang, Y. (2026). ALKBH5 activates creatine-driven thermogenesis by stabilizing CKB mRNA in response to cold. Nature Metabolism. https://doi.org/10.1038/s42255-026-01592-y

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01592-y

Keywords: ALKBH5, thermogenesis, brown fat, m6A methylation, CKB, creatine kinase, UCP1, obesity, YTHDF2, norepinephrine, CREB signaling, metabolism